StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross jointly filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of approximately 9.9% of the American Depositary Shares of Quoin Pharmaceuticals Ltd. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each reporting person is listed as beneficially owning 506,983 American Depositary Shares (ADS) of Quoin Pharmaceuticals Ltd.
  • Ownership percentage: The 506,983 ADS represent 9.9% of the class, rounded down from the calculated figure due to EDGAR field limitations, according to the filing.
  • Composition of holdings: The 506,983 ADS consist of 236,234 ADS held directly, 173,596 ADS obtainable through pre-funded warrants, and 97,153 ADS underlying warrants subject to a 9.99% beneficial ownership limitation.
  • Excluded shares: 107,762 ADS underlying pre-funded warrants are excluded from the reported total due to the beneficial ownership limitation.
  • No sole voting or dispositive power: All voting and dispositive power is reported as shared among the reporting persons, with zero sole power reported by any party.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.

StemPoint Capital and Michelle Ross Report Joint Ownership in Quoin Pharmaceuticals ADS

According to the Schedule 13G filed on November 16, 2026, three reporting persons - StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross - jointly disclosed beneficial ownership of 506,983 American Depositary Shares of Quoin Pharmaceuticals Ltd. Each ADS represents thirty-five (35) ordinary shares with no par value. The securities carry CUSIP number 74907L409. The filing identifies the event date requiring this statement as September 30, 2026.

The filing states that the 506,983 ADS are composed of three components: (i) 236,234 ADS held directly, (ii) 173,596 ADS obtainable through the exercise of pre-funded warrants, and (iii) 97,153 ADS underlying warrants subject to a 9.99% beneficial ownership limitation. The filing notes that 107,762 ADS underlying pre-funded warrants are excluded from the reported total because of that same beneficial ownership limitation. The 9.9% ownership percentage is calculated against a base of 4,804,161 ADS outstanding as of September 16, 2026, as disclosed in the issuer's prospectus filed with the SEC on September 25, 2026, plus the exercisable warrant shares.

All three reporting persons share the same business address at 520 Madison Avenue, 19th Floor, New York, NY 10022. StemPoint Capital LP is classified as a Delaware limited partnership, StemPoint Capital Management GP LLC is a Delaware limited liability company, and Michelle Ross is identified as a U.S. citizen. The filing was signed by Sean C. Tan as authorized signatory for both StemPoint entities and by Michelle Ross individually. The reporting persons certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross filed a joint Schedule 13G disclosing aggregate beneficial ownership of 506,983 ADS, equating to 9.9%, of Quoin Pharmaceuticals Ltd. as of the September 30, 2026 event date.